AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30866676 — intervention group
Group type: COMPARATOR
Intervention: Published averages for academic medical centers
Number of subjects: 13
Study 30866676 — intervention group
Group type: COMPARATOR
Intervention: Published averages for enrollment
Number of subjects: 13
Study 30866676 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder satisfaction with reliance experience
Number of subjects: 13
Study 30866879 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAsk mHealth intervention
Number of subjects: 66
Study 30866942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 187
Study 30866994 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a stabilizing connecting device for ultrasound transducer
Number of subjects: 0
Study 30866994 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulated blood from the patient as an alternative for ultrasound gel
Number of subjects: 0
Study 30867154 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I (hs-cTnI) assay
Number of subjects: 20000
Study 30867337 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced REM sleep
Number of subjects: 1234
Study 30867337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest REM quartile group
Number of subjects: 1234
Study 30867337 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest REM quartile group
Number of subjects: 1234
Study 30867794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-tumor AvidinOX with low systemic dose biotinylated cetuximab (bCet)
Number of subjects: 0
Study 30867794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-tumor AvidinOX with low systemic dose biotinylated cetuximab (bCet) plus low dose cisplatin
Number of subjects: 0
Study 30867794 — intervention group
Group type: COMPARATOR
Intervention: Low systemic dose biotinylated cetuximab (bCet) without AvidinOX
Number of subjects: 0
Study 30867935 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Childbirth Checklist (SCC) program implemented in 19 intervention facilities with monthly supportive supervision and supply of drugs and equipment.
Number of subjects: 77
Study 30867935 — intervention group
Group type: COMPARATOR
Intervention: Routine care provided in 15 comparison facilities without the SCC program.
Number of subjects: 77
Study 30868245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) 300/120 mg for 8 weeks
Number of subjects: 899
Study 30868419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.07%
Number of subjects: 49
Study 30868419 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.3%
Number of subjects: 49
Study 30868475 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus PEMF therapy
Number of subjects: 42
Study 30868475 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus sham
Number of subjects: 42
Study 30868550 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 660
Study 30868550 — intervention group
Group type: COMPARATOR
Intervention: Tumor Necrosis Factor Inhibitors (TNFis)
Number of subjects: 660
Study 30869114 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood protein intake (mean 58.3 g/d)
Number of subjects: 1165
Study 30869114 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood protein intake
Number of subjects: 1165
Study 30869127 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine treatment
Number of subjects: 47
Study 30870275 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implants
Number of subjects: 350
Study 30870275 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A7*1C variant
Number of subjects: 350
Study 30871357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CABG patients (n=1101)
Number of subjects: 3486
Study 30871357 — intervention group
Group type: COMPARATOR
Intervention: No prior CABG patients (n=2317)
Number of subjects: 3486
Study 30871358 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI
Number of subjects: 10982
Study 30871413 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on PrEP service delivery using a two-day case-based interactive curriculum
Number of subjects: 716
Study 30871484 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation group (EIG)
Number of subjects: 444
Study 30871484 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation group (DIG)
Number of subjects: 444
Study 30871493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg Q2W) followed by nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W) after a 3-cycle run-in phase.
Number of subjects: 75
Study 30871493 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (240 mg Q2W) only for patients not escalated to ipilimumab.
Number of subjects: 75
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 2833
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 2833
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring with opioid, propofol, and nitrous oxide
Number of subjects: 2833
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane concentration with BIS monitoring
Number of subjects: 2833
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2833
Study 30871507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid onset OCR
Number of subjects: 2833
Study 30871693 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo contrast-enhanced CT angiography
Number of subjects: 0
Study 30871768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) treatment
Number of subjects: 0
Study 30871768 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (n = 26)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + Med (n = 25)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (n = 54)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + Med (n = 54)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (short sleep duration)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + Med (short sleep duration)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (normal sleep duration)
Number of subjects: 159
Study 30871960 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + Med (normal sleep duration)
Number of subjects: 159
Study 30872042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) measured at index visit and at a 12-month interval
Number of subjects: 169
Study 30872087 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNB
Number of subjects: 39
Study 30872087 — intervention group
Group type: COMPARATOR
Intervention: Unroofing biopsy
Number of subjects: 39
Study 30872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with mild hepatic impairment
Number of subjects: 0
Study 30872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with moderate hepatic impairment
Number of subjects: 0
Study 30872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with normal hepatic function
Number of subjects: 0
Study 30872388 — intervention group
Group type: COMPARATOR
Intervention: Population PK analysis of osimertinib
Number of subjects: 0
Study 30872988 — intervention group
Group type: EXPERIMENTAL
Intervention: Janssen Autism Knowledge Engine (JAKE)
Number of subjects: 0
Study 30873017 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable whole-limb machine-based resistance training (S-MRT)
Number of subjects: 68
Study 30873017 — intervention group
Group type: EXPERIMENTAL
Intervention: Instability free-weight resistance training (I-FRT)
Number of subjects: 68
Study 30873017 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable machine-based adductor/abductor resistance training (S-MRT)
Number of subjects: 68
Study 30873106 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Inversion Recovery MRI
Number of subjects: 0
Study 30873285 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, emails, and mailed incentives (4 HV)
Number of subjects: 44
Study 30873285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 home visits, emails, and mailed incentives (2 HV)
Number of subjects: 44
Study 30873285 — intervention group
Group type: COMPARATOR
Intervention: General health emails (control)
Number of subjects: 44
Study 30873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder supplemented with calcium and vitamin D and periodontal therapy (PT)
Number of subjects: 0
Study 30873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment and consumption of milk fortified with calcium-vitamin D
Number of subjects: 0
Study 30873378 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban for primary prevention of VTE
Number of subjects: 0
Study 30873378 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 30873623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) ± antiplatelet (AP) therapy
Number of subjects: 4162
Study 30873623 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VKA oral anticoagulant (NOAC) ± AP
Number of subjects: 4162
Study 30873623 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet (AP) only
Number of subjects: 4162
Study 30873623 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic treatment
Number of subjects: 4162
Study 30873623 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 4162
Study 30873942 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1117
Study 30875094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg + Osimertinib 80 mg single dose on days 1 and 39 and Osimertinib 80 mg once daily from days 4 to 41
Number of subjects: 24
Study 30875094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg + Osimertinib 80 mg at steady state
Number of subjects: 24
Study 30875094 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 24
Study 30876390 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC/AHA 2013 cholesterol guidelines
Number of subjects: 4378
Study 30876390 — intervention group
Group type: COMPARATOR
Intervention: NCEP-ATP recommendations
Number of subjects: 4378
Study 30876442 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin) at Maximum Tolerated Dose (MTD) of 59.92Gy/2.14Gy/28f
Number of subjects: 53
Study 30876442 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin)
Number of subjects: 53
Study 30876442 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy
Number of subjects: 53
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: sIMRT (step-and-shoot intensity-modulated radiotherapy)
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: dIMRT (dynamic intensity-modulated radiation therapy)
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (volumetric-modulated arc therapy)
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomo (helical tomotherapy)
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: All four radiotherapy modalities
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomo
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: sIMRT and dIMRT
Number of subjects: 10
Study 30876444 — intervention group
Group type: EXPERIMENTAL
Intervention: All four approaches
Number of subjects: 10
Study 30876459 — intervention group
Group type: COMPARATOR
Intervention: Pericardial closure using ECM in valve surgery
Number of subjects: 1420
Study 30876459 — intervention group
Group type: COMPARATOR
Intervention: Pericardial closure using ECM in CABG surgery
Number of subjects: 1420
Study 30876459 — intervention group
Group type: COMPARATOR
Intervention: Pericardial closure using ECM in both valve and CABG surgery
Number of subjects: 1420
Study 30876459 — intervention group
Group type: COMPARATOR
Intervention: Postoperative atrial fibrillation in CABG patients
Number of subjects: 1420
Study 30876459 — intervention group
Group type: COMPARATOR
Intervention: Postoperative atrial fibrillation in valve patients
Number of subjects: 1420
Study 30876475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 938
Study 30876475 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 938
Study 30876480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool DNA-based SDC2 methylation test (meSDC2 LTE-qMSP)
Number of subjects: 585
Study 30876830 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological tests including spirometry, body plethysmography, impulse oscillometry, and multiple breath nitrogen washout
Number of subjects: 872
Study 30876830 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry and spirometry
Number of subjects: 872
Study 30876830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acinar airway ventilation heterogeneity
Number of subjects: 872
Study 30876830 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological measures
Number of subjects: 872
Study 30877130 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive scleral excision surgery (scleral window surgeries), removing 90% of the scleral thickness for 3 and 1/4 quadrants.
Number of subjects: 5
Study 30877130 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive scleral excision surgery (scleral window surgeries)
Number of subjects: 5
Study 30877202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy, administered via injections at weeks 0, 4, and 8
Number of subjects: 18
Study 30877221 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Intermittent and Constant Osteoarthritis Pain (ICOAP) questionnaire
Number of subjects: 300
Study 30877221 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ICOAP-hand questionnaire
Number of subjects: 300
Study 30877221 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 300
Study 30877569 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg single-dose
Number of subjects: 44
Study 30877569 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 44
Study 30877569 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg twice daily
Number of subjects: 44
Study 30877753 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count ≥500 cells/µL
Number of subjects: 1901
Study 30877753 — intervention group
Group type: COMPARATOR
Intervention: CD4 count 200-499 cells/µL
Number of subjects: 1901
Study 30877753 — intervention group
Group type: COMPARATOR
Intervention: CD4 count <200 cells/µL
Number of subjects: 1901
Study 30877780 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth self-management intervention for chronic pain
Number of subjects: 20
Study 30878250 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30878319 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation 400 cGy
Number of subjects: 17
Study 30878319 — intervention group
Group type: COMPARATOR
Intervention: Total body irradiation 200 cGy (previous standard)
Number of subjects: 17
Study 30878406 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound training
Number of subjects: 0
Study 30878406 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of point-of-care ultrasound
Number of subjects: 0
Study 30878422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging-derived right ventricular (RV) strain
Number of subjects: 38
Study 30878475 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 811
Study 30878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field examinations in groups 1-6
Number of subjects: 80
Study 30878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field examinations in group 7
Number of subjects: 80
Study 30878986 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field examinations
Number of subjects: 80
Study 30878987 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid expansion
Number of subjects: 0
Study 30878987 — intervention group
Group type: COMPARATOR
Intervention: No Medicaid expansion
Number of subjects: 0
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative spirometry with airflow obstruction defined as FEV1/FVC ratio below LLN
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative spirometry with FEV1 < LLN
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cardiopulmonary bypass time
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced kidney function
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 < LLN
Number of subjects: 551
Study 30879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative spirometry
Number of subjects: 551
Study 30879050 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized pulmonary homografts (DPH)
Number of subjects: 121
Study 30879050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DPH cohort (n=235)
Number of subjects: 121
Study 30879050 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved homografts (CH)
Number of subjects: 121
Study 30879050 — intervention group
Group type: COMPARATOR
Intervention: Bovine jugular vein (BJV)
Number of subjects: 121
Study 30879249 — intervention group
Group type: EXPERIMENTAL
Intervention: AVXS-101
Number of subjects: 0
Study 30879256 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 2550
Study 30879511 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean delivery
Number of subjects: 3792
Study 30879757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 228
Study 30879757 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 228
Study 30879790 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT® AAA Stent Graft System
Number of subjects: 0
Study 30879929 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced intra-operative ultrasound (CE-IOUS) using sulphur hexafluoride microbubbles
Number of subjects: 54
Study 30879929 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative ultrasound (IOUS)
Number of subjects: 54
Study 30879979 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine (three doses on Day 1, Month 2, Month 6)
Number of subjects: 1030
Study 30879979 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 1030
Study 30880509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot fertility app (Dynamic Optimal Timing)
Number of subjects: 718
Study 30880554 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy program
Number of subjects: 0
Study 30880554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30881101 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensor training
Number of subjects: 54
Study 30881101 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor training
Number of subjects: 54
Study 30881101 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 54
Study 30881102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.1 mg
Number of subjects: 0
Study 30881102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg
Number of subjects: 0
Study 30881102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine 0.5 mg
Number of subjects: 0
Study 30881102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30881102 — intervention group
Group type: COMPARATOR
Intervention: Morphine 4 mg
Number of subjects: 0
Study 30881452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (25 mg IM once a month for 6 years)
Number of subjects: 60
Study 30881909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated-dose spinal anesthesia injection
Number of subjects: 42
Study 30881909 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia injection
Number of subjects: 42
Study 30881948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation monitoring during intubation
Number of subjects: 0
Study 30882062 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal surveys including diet, child temperament, family environment, and child care at 6 weeks, 3, 12, 18, 24, 36, 48, and 60 months.
Number of subjects: 468
Study 30882062 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's birth weight and intent to breastfeed collected at 1-week home visit.
Number of subjects: 468
Study 30882062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool samples of the child collected at each visit, saliva at 1 visit.
Number of subjects: 468
Study 30882240 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 30882240 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30882352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based mindfulness and social support program
Number of subjects: 37